HEYLTEX is the US Subsidiary of HEYL, a family-owned pharmaceutical company that specializes in the development, manufacturing and distribution of CBRN Medical Countermeasures. Founded in 1926 in Berlin, Germany, HEYL has grown into a global leader for the treatment of patients following a radiological or nuclear incident. Today, HEYL is active across the full CBRN threat spectrum, offering medical countermeasures and related products to respond to chemical and biological threats, in addition to its radiological and nuclear portfolio.